NCT01677455 2015-11-05
Enchant
Synta Pharmaceuticals Corp.
Phase 2 Completed
Clinical Trials
6 trialsNCT01031225 2014-09-19
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Synta Pharmaceuticals Corp.
Phase 2 Completed
NCT01183364 2014-09-19
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00687934 2014-09-18
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00858572 2014-09-18
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00964873 2014-09-18
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
Synta Pharmaceuticals Corp.
Phase 1 Completed